Spyre Therapeutics, Inc. - Common Stock SYRE 深 滬
交易中 12-16 10:41:14 美东时间
32.61
-0.730
-2.19%
華盛通- 最 高33.52
- 今 開33.00
- 成交量 5.51万股
- 最 低 32.572
- 昨 收 33.34
- 總市值 25.30亿
- 52周最高 35.31
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 10.91
- 委 比 50.34%
- 總股本 7759.21万
- 歷史最高 318.75
- 量 比 0.48
- 振 幅 2.84%
- 歷史最低 2.66
- 每 手 1
- 風險率 4.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
Jones Trading Upgrades Spyre Therapeutics to Buy, Announces $64 Price Target
Jones Trading analyst Debanjana Chatterjee upgrades Spyre Therapeutics (NASDAQ:SYRE) from Hold to Buy and announces $64 price target.
12-01 21:17
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
<p>Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotech company focused on long-acting antibodies for inflammatory bowel disease and rheumatic diseases, announced that its management will attend three upcoming investor conferences in November 2025. The events include the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, the Stifel 2025 Healthcare Conference in New York, and the Jefferies Global Healthcare Conference i...
10-29 20:05
Spyre Therapeutics Releases New Data From Its Phase 1 Study Of SPY072, An anti-TL1a Antibody For Rheumatic Diseases Showing SPY072 Was Well Tolerated, Maintained Strong Tl1a Suppression, And Supports Quarterly Or Twice-Yearly Dosing
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and
10-24 20:04
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
Spyre Therapeutics announced scientific presentations at the ACR Convergence Congress, sharing Phase 1 data on SPY072, an anti-TL1A agent for rheumatic diseases. The data showed SPY072 is well-tolerated, with a PK profile supporting quarterly or twice-yearly dosing, and suppressed free TL1A at the lowest dose. Additionally, preclinical data demonstrated SPY072's efficacy, meeting or exceeding etanercept in a rodent arthritis model, supporting ong...
10-24 12:00
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
Spyre Therapeutics, a clinical-stage biotech company focused on treating inflammatory bowel disease and other immune-mediated conditions, announce the closing of its underwritten public offering. The company sold 17,094,594 shares, including 2,229,729 additional shares due to underwriters' option exercise, at $18.50 per share, resulting in approximately $316.2 million in gross proceeds. Jefferies, TD Securities, Leerink Partners, and Stifel acted...
10-15 20:15
Spyre Therapeutics Reveals Proposed Public Offering of its Common Stock And Pre-Funded Warrants; No Size Disclosed
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization,
10-14 04:03
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. announced the pricing of its underwritten public offering of 14,864,865 shares of common stock at $18.50 per share, with expected gross proceeds of approximately $275 million. The offering includes an option for underwriters to purchase up to an additional 2,229,729 shares. Spyre, a clinical-stage biotech company focused on antibody engineering and immune-mediated diseases...
10-14 01:07
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
Spyre Therapeutics announced scientific presentations at the UEGW Congress, highlighting interim Phase 1 results for SPY002, an anti-TL1A agent for IBD, showing it is well-tolerated with a potential for quarterly or twice-yearly dosing. The company also presented preclinical data demonstrating the superior efficacy of combination therapies targeting α4β7, TL1A, and IL-23 in colitis models, supporting the ongoing SKYLINE-UC Phase 2 study. Full ses...
10-05 13:00
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
